Patents by Inventor Johanna M. Rommens
Johanna M. Rommens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6440699Abstract: A human gene which is here named CA7 CG04 has been identified in which mutations have been found which have been correlated with prostate cancer.Type: GrantFiled: May 11, 2000Date of Patent: August 27, 2002Assignees: Myriad Genetics, Inc., Hospital for Sick Children, TheInventors: Sean V. Tavtigian, Brad Swedlund, Jacques Simard, Johanna M. Rommens
-
Patent number: 6395960Abstract: The present invention describes the identification, isolation and cloning of two human presenilin genes, PS-1 and PS-2, mutations in which lead to Familial Alzheimer's Disease. Also identified are presenilin homologue genes in mice, C. elegans and D. melanogaster. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the constructions of transgenic animals expressing the mutant genes.Type: GrantFiled: July 29, 1998Date of Patent: May 28, 2002Assignees: The Hospital for sick Children, HSC Research and Development Limited Partnership, The Geverning Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 6333403Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers.Type: GrantFiled: May 5, 2000Date of Patent: December 25, 2001Assignees: Myriad Genetics, Inc., The Hospital for Sick ChildrenInventors: Sean V. Tavtigian, David H. F. Teng, Jacques Simard, Johanna M. Rommens
-
Patent number: 6210919Abstract: The present invention describes the identification, isolation, cloning, and sequencing of the Alzheimer Related Membrane Protein (ARMP) gene for both normal and mutant forms. An analogous mouse gene, mARMP gene, has also been isolated, cloned, and sequenced. The gene transcript and gene products are used in developing DNA diagnosis for and detection of carriers of the gene, Alzheimer's Disease diagnosis, gene therapy, protein therapy, immunotherapy, as well as the isolation and manufacture of the protein and the development of transgenic animals carrying mutations in the ARMP gene.Type: GrantFiled: June 28, 1995Date of Patent: April 3, 2001Assignee: HSC Research and Development Limited PartnershipInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 6201107Abstract: The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.Type: GrantFiled: June 6, 1995Date of Patent: March 13, 2001Assignees: HSC Research Development Corporation, The Board of Regents, Acting for and on Behalf of the University of MichiganInventors: Tsui Lap-Chee, John R. Riordan, Francis S. Collins, Johanna M. Rommens, Michael C. Iannuzzi, Bat-Sheva Kerem, Mitchell L. Drumm, Manuel Buchwald
-
Patent number: 6194153Abstract: The present invention describes the identification, isolation and cloning of two human presenilin genes, PS-1 and PS-2, mutations in which lead to Familial Alzheimer's Disease. Also identified are presenilin homologue genes in mice, C. elegans and D. melanogaster. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the constructions of transgenic animals expressing the mutant genes.Type: GrantFiled: July 31, 1998Date of Patent: February 27, 2001Assignees: The Hospital for Sick Children, HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 6124104Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics.Type: GrantFiled: March 20, 1998Date of Patent: September 26, 2000Assignees: Myriad Genectics, Inc., Endo Recherche, Inc., HSC Reseach & Development Limited Partnership, Trustees of the University of PennsylvaniaInventors: Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M. Rommens, Barbara L. Weber
-
Patent number: 6117978Abstract: The present invention describes the identification, isolation and cloning of two human presenilin genes, PS-1 and PS-2, mutations in which lead to Familial Alzheimer's Disease. Also identified are presenilin homologue genes in mice, C. elegans and D. melanogaster. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the constructions of transgenic animals expressing the mutant genes.Type: GrantFiled: July 29, 1998Date of Patent: September 12, 2000Assignees: The Governing Council of the University of Toronto, HSC Research and Development Limited PartnershipInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 6063913Abstract: A modified DNA sequence encoding full length cystic fibrosis transmembrane conductance regulator protein is provided to facilitate propagation and/or expression of the protein in living cells and in particular, bacterial cells. The modified DNA sequence comprises at least one of the 13 base pair repeat of exon 6b of the normal gene encoding the conductance regulator protein, as one or more normal nucleotides of the 13 base repeat substituted with an alternate nucleotide which, however, continues to code for the corresponding normal amino acid. Mammalian cells transfected with a vector containing the modified DNA sequence enhances chlorine conductance through the cell wall.Type: GrantFiled: April 12, 1993Date of Patent: May 16, 2000Assignee: HSC Research and Development Limited PartnershipInventors: Lap-Chee Tsui, Johanna M. Rommens
-
Patent number: 6033857Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics.Type: GrantFiled: March 20, 1998Date of Patent: March 7, 2000Assignees: Myriad Genetics, Inc., Endo Recherche, Inc., HSC Research & Development Limited Parntership, Trustees of the Univ. of PennsylvaniaInventors: Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M. Rommens, Barbara L. Weber
-
Patent number: 6020143Abstract: The identification, isolation, sequencing and characterization of two human presenilin genes, PS-1 and PS-2, mutations in which lead to Familial Alzheimer's Disease, are disclosed. Presenilin gene homologs in mice, C. elegans and D. melanogaster are also disclosed. Use of the nucleic acids and proteins comprising or derived from the presenilins in screening and diagnosing Alzheimer's Disease, identifying and developing therapeutics for treatment of Alzheimer's Disease, in producing cell lines and transgenic animals useful as models of Alzheimer's Disease. Methods for identifying substances that bind to, or modulate the activity of, a presenilin protein, functional fragment or variant thereof, or a mutein thereof, and methods for identifying substances that affect the interaction of a presenilin-interacting protein with a presenilin protein, functional fragment or variant thereof, or a mutein thereof, are further disclosed.Type: GrantFiled: July 3, 1997Date of Patent: February 1, 2000Assignee: Research and Development Limited PartnershipInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 6001588Abstract: The identification, isolation and cloning of DNA sequences coding for mutant forms of the cystic fibrosis gene and their gene product are described. DNA sequence information and information relating to the genomic structure of the cystic fibrosis gene are provided. The mutant forms of the CF gene include specific sequence alterations in coding portions or of other genetic information at exon/intron boundaries and altered RNA transcripts and mutant protein products. Such DNA and protein information is useful in developing DNA or protein diagnosis for CF mutations, carrier and patient screening, as well as cloning of mutant genes and manufacturing of their proteins for investigation into therapies for cystic fibrosis.Type: GrantFiled: July 13, 1992Date of Patent: December 14, 1999Assignee: HSC Research Development CorporationInventors: Lap-Chee Tsui, Johanna M. Rommens, Bat-sheva Kerem
-
Patent number: 5986054Abstract: The present invention describes the identification, isolation and cloning of two human presenilin genes, PS-1 and PS-2, mutations in which lead to Familial Alzheimer's Disease. Also identified are presenilin homologue genes in mice, C. elegans and D. melanogaster. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the constructions of transgenic animals expressing the mutant genes.Type: GrantFiled: January 26, 1996Date of Patent: November 16, 1999Assignees: The Hospital for Sick Children, HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 5981178Abstract: The cystic fibrosis gene and its gene product are described for mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.Type: GrantFiled: June 6, 1995Date of Patent: November 9, 1999Assignee: HSC Research Development CorporationInventors: Lap-Chee Tsui, Johanna M. Rommens, Bat-sheva Kerem
-
Patent number: 5863770Abstract: A modified DNA sequence encoding full length cystic fibrosis transmembrane conductance regulator protein is provided to facilitate propagation and/or expression of the protein in living cells and in particular, bacterial cells. The modified DNA sequence comprises at least one of the 13 base pair repeat of exon 6b of the normal gene encoding the conductance regulator protein, as one or more normal nucleotides of the 13 base repeat substituted with an alternate nucleotide which, however, continues to code for the corresponding normal amino acid.Type: GrantFiled: February 21, 1996Date of Patent: January 26, 1999Assignee: HSC Research and Development Limited PartnershipInventors: Lap-Chee Tsui, Johanna M. Rommens
-
Patent number: 5840540Abstract: The present invention describes the identification, isolation and cloning of two human presenilin genes, PS-1 and PS-2, mutations in which lead to Familial Alzheimer's Disease. Also identified are presenilin homologue genes in mice, C. elegans and D. melanogaster. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the constructions of transgenic animals expressing the mutant genes.Type: GrantFiled: November 10, 1997Date of Patent: November 24, 1998Assignees: The Hospital for Sick Children, HSC Research and Development Limited PartnershipInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 5837492Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics.Type: GrantFiled: April 29, 1996Date of Patent: November 17, 1998Assignees: Myriad Genetics, Inc., Endo Recherche, Inc., HSC Research & Development Limited Partnership, Trustees of the University of PennsylvainaInventors: Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M. Rommens, Barbara L. Weber
-
Patent number: 5776677Abstract: The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.Type: GrantFiled: June 6, 1995Date of Patent: July 7, 1998Assignees: HSC Research Development Corporation, The Board of Regents, Acting for and on Behalf of The University of MichiganInventors: Lap-Chee Tsui, John R. Riordan, Francis S. Collins, Johanna M. Rommens, Michael C. Iannuzzi, Bat-Sheva Kerem, Mitchell L. Drumm, Manuel Buchwald
-
Patent number: 5534438Abstract: The underlying genetic defect of Huntington disease (HD) has been mapped to chromosomal band 4.sub.p 16.3. Refined localization using recombinant HD chromosome analysis and allelic association analyses have identified two distinct candidate regions. Using a cDNA hybrid selection procedure, .alpha.-adducin has been mapped to the proximal 2.2 Mb 4D gene candidate region within 20 kb of D4S95. Several clones have been mapped within the minimal region containing the HD gene. The clones GT 70 and GT 149 are particularly useful in detecting changes in this portion of the gene of HD patients.Type: GrantFiled: September 24, 1993Date of Patent: July 9, 1996Assignees: University of British Columbia, HSC Research & Development Ltd.Inventors: Michael Hayden, Paul Goldberg, Susan Andrew, Johanna M. Rommens